Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers

Authors: Tomaka, F¹; Lefebvre, E²; Sekar, V¹; Van Baelen, B³; Vangeneugden, T³; Vandevoorde, A³; Diego Miralles, G³

Source: HIV Medicine, Volume 10, Number 5, May 2009 , pp. 318-327(10)

Publisher: Wiley-Blackwell

Abstract:

Background

Darunavir (TMC114) is a new HIV protease inhibitor (PI). Design

This Phase I, randomized, open-label trial compared the effects of darunavir plus low-dose ritonavir (RTV) (darunavir/RTV) with those of atazanavir/RTV on lipid and glucose parameters. Methods

Forty-nine HIV-negative, healthy male volunteers received RTV 100 mg once a day (qd) for 7 days, followed by either darunavir/RTV 800/100 mg qd (n=25) or atazanavir/RTV 300/100 mg qd (n=24) for 21 days. Mean changes in fasting lipid and glucose parameters at day 28 were calculated using post-RTV alone (day 7) and baseline (day −1) values as references. Short-term safety, tolerability and RTV pharmacokinetic parameters were evaluated. Results

After 7 days of RTV treatment, the mean triglyceride concentration increased by approximately 30 mg/dL in both groups, changes in other lipid and glucose parameters were relatively small. Mean concentrations of lipids and glucose over the treatment period were mostly similar between the treatment groups. Mean changes from day 7 to day 28 for the darunavir/RTV and atazanavir/RTV groups, respectively, were −3.6 and −0.5 mg/dL for high-density lipoprotein cholesterol; 5.0 and 5.3 mg/dL for low-density lipoprotein cholesterol; 4.9 and 1.2 mg/dL for total cholesterol; 6.4 and 14.0 mg/dL for triglycerides; −1.7 and −2.4 mg/dL for glucose; and −1.4 and 0.3 mg/dL for insulin. No grade 3 or 4 lipid or glucose laboratory abnormalities were reported. Treatment-emergent hyperbilirubinaemia was reported for all volunteers (including five grade 4 cases) during atazanavir/RTV treatment. Conclusions

Co-administration of darunavir or atazanavir with low-dose RTV resulted in minor and similar changes in lipid and glucose parameters in HIV-negative healthy volunteers.

Keywords: atazanavir; darunavir; HIV; lipids; metabolic; protease inhibitors; TMC114

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1468-1293.2008.00690.x

Affiliations: 1: Tibotec Inc., Yardley, PA, USA, 2: Janssen-Cilag BV, Tilburg, the Netherlands and 3: Tibotec BVBA, Mechelen, Belgium

Publication date: 2009-05-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Allergy & Immunology ,  Internal Medicine ,  Pediatrics
• By this author: Tomaka, F ;  Lefebvre, E ;  Sekar, V ;  Van Baelen, B ;  Vangeneugden, T ;  Vandevoorde, A ;  Diego Miralles, G

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers